Risk factors for selection of the L74I reverse transcriptase mutation in human immunodeficiency virus type 1-infected patients.
We analyzed 3,475 human immunodeficiency virus sequences and 241 therapeutic histories. The L74I mutation was carried by 7% of viruses. L74I was strongly associated with T215F, K70R, and V75M/S/T/A mutations and increased with the number of thymidine analog mutations. It seemed to be linked to the use of abacavir or efavirenz.
Wirden
Marc
M
Department of Virology, Pitié-Salpêtrière Hospital, 75013 Paris, France. marc.wirden@psl.aphp.fr
Roquebert
Bénédicte
B
Derache
Anne
A
Simon
Anne
A
Duvivier
Claudine
C
Ghosn
Jade
J
Dominguez
Stephanie
S
Boutonnet
Véronique
V
Ait-Arkoub
Zaina
Z
Katlama
Christine
C
Calvez
Vincent
V
Marcelin
Anne-Genevieve
AG
D000480:Alkynes; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D048588:Benzoxazines; D003521:Cyclopropanes; D015224:Dideoxynucleosides / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy / Q000821:virology*; D054303:HIV Reverse Transcriptase / Q000235:genetics*; D015497:HIV-1 / Q000187:drug effects / Q000201:enzymology* / Q000235:genetics; D006801:Humans; D009154:Mutation; D010078:Oxazines / Q000627:therapeutic use*; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D012307:Risk Factors; D000099227:Abacavir
D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D015224:Dideoxynucleosides; D054303:HIV Reverse Transcriptase; D010078:Oxazines; D018894:Reverse Transcriptase Inhibitors; D000099227:Abacavir; C098320:efavirenz